« Previous article
Webinar: How the New...

29th December 2020  Product update: rapidmicrobiology staff writer

Co-Diagnostics Designs Test to Detect New Coronavirus Strain Mutations

Co-Diagnostics, Inc. has completed the principal design work for a PCR test that would allow researchers to identify certain mutations in a newly detected variant of SARS-CoV-2 known as VUI 202012/01.

The new coronavirus strain comprises several mutations and may be more contagious than its predecessors. Dwight Egan, CEO of Co-Diagnostics, commented "One of the most important advantages of our CoPrimerâ„¢ platform is its ability to reliably and accurately differentiate between similar genetic sequences, in order to reduce the likelihood of a false positive diagnosis. The multiplexing capabilities of our CoPrimer platform go hand-in-glove with the technology's applications in detecting small genetic variations in a given gene. As we have demonstrated earlier on during this pandemic, our technology also facilitates rapid test development that we believe could help get testing solutions on the ground quickly as impactful mutations are identified."

Co-Diagnostics also confirmed that the genetic mutations in the new variant are not believed to interfere with the performance of the Company's existing line of COVID-19 diagnostics, and that any new test developed for this mutation would be a separate product, distinct from the Company's other tests.

Visit codiagnostics.com/products/diagnostic-solutions/logix-smart-covid19/



Date Published: 29th December 2020

Source article link: View

Note: This content has been edited by a rapidmicrobiology staff writer for style and content.

View full company details